Literature DB >> 8428336

Quality of life in patients with prostatic cancer. A feasibility study. The Members of Quality of Life Committee of the EORTC Genitourinary Group.

F C da Silva1, E Reis, T Costa, L Denis.   

Abstract

BACKGROUND: In recent years, there has been a growing recognition of the need to include parameters representing the patients' view of their conditions that, therefore, are more subjective in nature.
METHODS: As a first effort to introduce quality-of-life (QOL) assessment in prostatic cancer clinical trials, the European Organization for Research and Treatment of Cancer (EORTC) Genitourinary Group, in cooperation with the EORTC QOL Group, activated Protocol 30853 (orchiectomy versus goserelin acetate and flutamide in previously untreated patients with Stage M+ disease. Study Coordinator: Louis Denis). The use of patient-administered QOL questionnaires was optional, and of 327 patients, only 22% underwent pretreatment assessments.
RESULTS: Psychologic distress, fatigue, social and family life, and pain are the most important to the patient on a subjective basis, and these were confirmed in relation to objective parameters. There was a discrepancy between the doctors' evaluations and the patients' opinions about subjective morbidity, namely, in regard to sexual status and pain.
CONCLUSIONS: This EORTC trial revealed the reluctance of clinicians to do QOL research, partly related to feasibility problems and partly to the doctors' doubts about the value of such efforts. QOL assessment should become a mandatory part of clinical trials in prostatic cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8428336     DOI: 10.1002/1097-0142(19930201)71:3+<1138::aid-cncr2820711436>3.0.co;2-7

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

Review 1.  [Quality of life after radical urologic pelvic surgery and impact of inpatient rehabilitation].

Authors:  O Dombo; U Otto
Journal:  Urologe A       Date:  2005-01       Impact factor: 0.639

2.  Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.

Authors:  Yoichi Arai; Hideyuki Akaza; Takashi Deguchi; Masato Fujisawa; Mikio Hayashi; Yoshihiko Hirao; Hiroshi Kanetake; Seiji Naito; Mikio Namiki; Masaaki Tachibana; Michiyuki Usami; Yasuo Ohashi
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-20       Impact factor: 4.553

Review 3.  Evaluation of quality of life for diverse patient populations.

Authors:  K R Yabroff; B P Linas; K Schulman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Pain caused by bone metastasis in endocrine-therapy-refractory prostate cancer.

Authors:  K Akakura; S Akimoto; J Shimazaki
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

5.  Quality of life bibliography and indexes: 1993 update.

Authors:  R A Berzon; G P Simeon; R L Simpson; M A Donnelly; H H Tilson
Journal:  Qual Life Res       Date:  1995-02       Impact factor: 4.147

Review 6.  Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment.

Authors:  Francesc Casas; Josep María Borràs; Ferran Ferrer; Núria Guanyabens; Rafael Gutiérrez del Pozo; Concha León; José López Torrecilla; Begoña Mellado; Joan Morote; Manel Puig; María José Ribal; Carme Ruscalleda; Agustí Serra; Valentí Valls; Almudena Zapatero
Journal:  Clin Transl Oncol       Date:  2010-05       Impact factor: 3.405

Review 7.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.

Authors:  R N Brogden; D Faulds
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

8.  Agreement between prostate cancer patients and their clinicians about utilities and attribute importance.

Authors:  Arthur S Elstein; Gretchen B Chapman; Joan S Chmiel; Sara J Knight; Cheeling Chan; Robert B Nadler; Timothy M Kuzel; Amy K Siston; Charles L Bennett
Journal:  Health Expect       Date:  2004-06       Impact factor: 3.377

9.  [Pain experience and pain therapy of tumor patients in the view of general practitioners].

Authors:  H Janig; W Pipam; S Lastin; R Sittl; G Bernatzky; R Likar
Journal:  Schmerz       Date:  2005-04       Impact factor: 1.107

10.  Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience.

Authors:  C Münger-Beyeler; J Bernhard; K Rufibach; R Morant; H-P Schmid
Journal:  Support Care Cancer       Date:  2007-10-02       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.